Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.

Mult Scler Relat Disord

Azienda Ospedaliero Universitaria Careggi, Dipartimento di Neuroscienze, Area del farmaco e Salute del bambino (NEUROFARBA), Largo Brambilla n 3, 50139 Florence, Italy. Electronic address:

Published: July 2017

Background: Severe multiple sclerosis reactivation following second line treatment withdrawal, defined "rebound syndrome", is becoming a prominent issue to consider when deciding to discontinue a treatment. In particular disease recurrence after cessation of fingolimod is actually poorly characterized as to date, only case reports and small case series have been described.

Case Presentation: We herewith describe 2 cases of severe disease reactivation associated to a high number of brain gadolinium enhancing lesions at magnetic resonance imaging (MRI) despite high dose steroid treatment, observed a few weeks after cessation of fingolimod administration, causing a substantial and persistent worsening of patient disability that required long term hospitalization. The severity of the neurological symptom worsening and of the brain lesion largely exceeded the disease activity observed during treatment.

Conclusions: Our patients developed a rebound syndrome after ceasing fingolimod treatment, defined as the development of severe neurological symptoms and multiple new or enhancing lesions exceeding previous activity. Further analysis are needed to identify patients at greatest risk of a rebound syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2017.05.003DOI Listing

Publication Analysis

Top Keywords

disease reactivation
8
multiple sclerosis
8
case reports
8
cessation fingolimod
8
enhancing lesions
8
rebound syndrome
8
disease
4
fingolimod
4
reactivation fingolimod
4
fingolimod withdrawal
4

Similar Publications

Co-inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), known as immune checkpoints, regulate the activity of T and myeloid cells during chronic viral infections and are well-established for their roles in cancer therapy. However, their involvement in chronic bacterial infections, particularly those caused by pathogens endemic to developing countries, such as Mycobacterium tuberculosis (Mtb), remains incompletely understood. Cytokine microenvironment determines the expression of co-inhibitory molecules in tuberculosis: Results indicate that the cytokine IL-12, in the presence of Mtb antigens, can enhance the expression of co-inhibitory molecules while preserving the effector and memory phenotypes of CD4+ T cells.

View Article and Find Full Text PDF

(), one of the most common infectious pathogens in the world, can cause gastritis, digestive ulcers, and even gastric cancer. urease (HPU) is a distinctive virulence factor of that allows it to be distinguished from other pathogens. Dried ginger is a famous edible and medicinal herb that is commonly used to prevent and treat gastrointestinal tract-related diseases.

View Article and Find Full Text PDF

Human endogenous retroviruses (HERVs) occupy a large portion of the human genome. Most HERVs are transcriptionally silent, but they can be reactivated during pathological states such as viral infection and certain cancers. The HERV-K HML-2 clade includes elements that recently integrated have in the human germ line and often contain intact open reading frames that possibly support peptide and protein expression.

View Article and Find Full Text PDF

Objective: Epstein-Barr virus (EBV) is a globally prevalent herpes virus associated with multiple diseases. Oxidative stress is closely related to EBV infection, latency, reactivation, and transformation. Antioxidant diet protects against EBV infection.

View Article and Find Full Text PDF

The outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) have improved with the implication of new in vivo and ex vivo graft-versus-host disease (GVHD) prophylaxis regimens. However, primary graft failure is still reported more frequently in haplo-HCT compared to a matched donor HCT. We conducted a pilot study (NCT04942730) to evaluate the impact of adding bendamustine to fludarabine and busulfan conditioning on engraftment after haplo-HCT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!